Phase 2 N=75 Trial of Dronabinol Adjunctive Treatment of Agitation in Alzheimer's Disease
Alzheimer's Disease
Primary: Symptoms of Agitation as Measured by the Pittsburgh Agitation Scale — 7.14; 5.55; 5.69; 4.97 score on a scale — p=.015
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=380 Dexmedetomidine in the Treatment of Agitation Associated With Bipolar Disorder
Agitation Associated With Bipolar Disorder · Agitation,Psychomotor · Bipolar Disorder
Primary: Change From Baseline in the Positive and Negative Syndrome Scale- Excited Component (PEC) Total Score — 18.0; 18.0; 17.9; -10.4 score on a scale — p=<0.0001
Phase 3 N=380 Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia
Agitation · Schizophrenia · Schizo Affective Disorder
Primary: Change From Baseline in the Positive and Negative Syndrome Scale- Excited Component (PEC) Total Score — 17.5; 17.6; 17.6; -8.4 score on a scale — p=<0.0001
Phase 3 N=387 Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Agitation in Patients With Dementia of the Alzheimer's Type
Primary: Stage 1 and Stage 2: Change From Baseline in the Cohen-Mansfield Agitation Inventory (CMAI) Composite Score to Week 6 and Week 12 — 73.9; 72.3; 71.7; -10.7 units on a…
Phase 3 N=522 Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Participants With Dementia of the Alzheimer's Type
Agitation in Participants With Dementia of the Alzheimer's Type
Primary: Change From Baseline to Week 12 in the Cohen-Mansfield Agitation Inventory (CMAI) Composite Score — 73.7; 68.8; 71.3; -16.2 score on a scale — p=0.789
N/A N=24 Alzheimer's in Long-Term Care--Treatment for Agitation
Alzheimer Disease · Psychomotor Agitation
Primary: Mean Clinical Global Impression of Change (CGIC) at Last Observation — 2.6; 4.5 units on a scale
Phase 3 N=366 Addressing Dementia Via Agitation-Centered Evaluation
Agitation in Patients With Dementia of the Alzheimer's Type · Alzheimer Disease · Agitation,Psychomotor
Primary: Change in CMAI Total Score — -15.4; -10.0; -11.5 score on a scale — p=0.010
Phase 2 N=77 Treatment of Psychosis and Agitation in Alzheimer's Disease
Alzheimer's Disease · Psychosis · Agitation
Primary: Change in Neuropsychiatric Inventory (NPI) Agitation/Aggression Domain Score — 3.2; 2.5 score on a scale — p=0.53
Phase 3 N=151 Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY II)
Agitation · Dementia
Primary: Absolute Change From Baseline in Positive and Negative Syndrome Scale- Excited Component (PEC) Total Score for the First Episode of Agitation — -5.7; -7.5; -5.4 score on…
Phase 2 N=35 Prazosin for Agitation in Alzheimer's Disease
Alzheimer's Disease · Disruptive Behavior
Primary: ADCS-Clinical Global Impression of Change in Agitation (ADCS-CGIC-A) — 3.434; 3.442 score on a scale — p=0.9904
Phase 3 N=186 Citalopram for Agitation in Alzheimer's Disease
Alzheimer's Disease · Agitation
Primary: NeuroBehavior Rating Scale-- Agitation — 4.33; 5.26 units on a scale — p=0.036
Phase 2 N=132 Treatment for Aggression and Agitation in Patients With Alzheimer's Disease
Alzheimer's Disease
Primary: Mean Change From Baseline in the 4-Item Agitation/Aggression Subscale of the Neuropsychiatric Inventory (NPI-4 A/A) at Week 12 — -5.4; -6.2 units on a scale
N/A N=20 Prazosin Treatment for Disruptive Agitation in Alzheimer's Disease
Alzheimer's Disease
Primary: Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change — 2.5; 2.43 units on a scale
N/A N=121 Emergence Agitation Between Dexmedetomidine and Sevoflurane Anesthesia
Emergence Delirium
Primary: Emergence Agitation — 3.9; 2.5 Score on a scale — p=0.001
Phase 3 N=203 Preventing Aggression in Veterans With Dementia
Dementia · Aggression · Pain
Primary: Number of Participants With Aggression as Determined by the Cohen-Mansfield Agitation Inventory (Aggression Subscale) — 8; 14; 9; 17 participants — p=0.13
Phase 3 N=410 Brexpiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type
Agitation Associated With Dementia of the Alzheimer's Type
Primary: Change From Baseline in Cohen-Manfield Agitation Inventory(CMAI) Score at 10 Weeks After Dosing. — -11.7; -15.2; -8.0 units on a scale — p=< 0.0001
Phase 4 N=72 A Comparison Study of the Efficacy of Quetiapine and Haloperidol in Agitated Adults in Emergency Room
Agitation
Primary: Change in the PANSS-EC Score Among Participants From Baseline to 2 Hours After Administration of the Medication. — -11.0; -11.5 score on a scale — p=>0.05
Phase 2 N=100 Sub-Lingual Dexmedetomidine in Agitation Associated With Dementia
Agitation,Psychomotor · Dementia
Primary: Mean Change From Baseline in Positive and Negative Syndrome Scale-Excited Component (PEC) Total Score — -5.4; -7.1; -2.9; -6.8 score on a scale — p=0.0813
Phase 4 N=120 Treating Acutely Agitated Patients With Asenapine Sublingual Tablets
Agitation
Primary: Positive and Negative Syndrome Scale - Excited Component — 7.86; 14.93 PANSS SCORE
Phase 2 N=350 Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Alzheimer's Disease
Primary: Change From Baseline in NPI-C Combined Agitation and Aggression Subscores (NPI-C A+A). — -4.3; -4.2 units on a scale
Phase 2 N=220 Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Participants With Alzheimer's Disease
Agitation · Alzheimer's Disease
Primary: Change in the Neuropsychiatric Inventory (NPI) Agitation/Aggression Domain Score From Day 1 (Stage 1 Baseline) to Day 36 (Stage 2 Baseline) and From Day 36 to Day 70…
Phase 3 N=345 A Trial to Evaluate the Safety, Efficacy, and Tolerability of Brexpiprazole in Treating Agitation Associated With Dementia of the Alzheimer's Type
Agitation Associated With Alzheimer's Dementia · Alzheimer Dementia
Primary: Change From Baseline to Week 12 in the CMAI Total Score — -22.6; -17.3 score on a scale — p=0.0026
Phase 2 N=78 A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease
Agitation and Aggression in Alzheimer's Disease
Primary: Treatment Emergent Adverse Events (TEAEs) — 53 Participants
Phase 2 N=129 Staccato Loxapine in Agitation (Proof of Concept)
Schizophrenia
Primary: PANSS-EC Change From Baseline — -4.98; -6.71; -8.56 PANSS units — p=0.0880
Phase 4 N=29 Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disorder
Bipolar Disorder · Schizophrenia · Agitation,Psychomotor
Primary: Change From Baseline in the Positive and Negative Syndrome Scale- Excited Component (PEC) Total Score — -10.4; -10.0; -10.1; -9.8 score on a scale
Phase 3 N=164 Brexpiprazole for the Long-term Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type
Agitation Associated With Dementia of the Alzheimer's Type
Primary: The Frequency of Subjects With Treatment-Emergent Adverse Events (TEAEs) — 90.2; 90.3 Percentage of percipitante
Phase 4 N=99 Propofol in Emergence Agitation
Emergence Agitation
Primary: Number of Participants With Emergent Agitation — 16; 24 Participants
Phase 3 N=259 A 12-week Extension Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type
Alzheimer's Disease
Primary: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) by Severity — 20.9; 13.5; 9.2; 19.8 percentage of participants
Phase 3 N=433 A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole in the Treatment of Alzheimer's Agitation
Agitation Associated With · Alzheimer's Disease · Alzheimer's Type
Primary: Change From Baseline In The Cohen-Mansfield Agitation Inventory (CMAI) Total Score After 12 Weeks Of Brexpiprazole Treatment — -21.6; -17.6; -17.8 units on a scale…
Phase 3 N=344 Staccato Loxapine in Agitated Patients With Schizophrenia
Patients With Schizophrenia and Acute Agitation
Primary: Change in PANSS-EC From Baseline — -5.5; -8.1; -8.6 units on a scale — p=0.0004